12 March 2018
The Orphan Drugs & Rare Diseases Global Congress 2018 Europe featured a discussion on real-world evidence (RWE).
7 March 2018
In 2014, Stallergenes Greer sought FDA approval for Oralair, a grass pollen sublingual immunotherapy, for use in patients aged five to 65 years of age – the same age range...
1 March 2018
On February 20th, Aimmune Therapeutics released topline data from its pivotal Phase III PALISADE trial assessing the efficacy and safety of its oral immunotherapy drug, AR-101, for the treatment of...
27 February 2018
Verastem’s duvelisib, which has Fast Track designation for relapsed or refractory chronic lymphocytic leukaemia (CLL), has been submitted for FDA approval to treat relapsed or refractory CLL and small lymphocytic...
26 February 2018
During 2017, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter -2 inhibitors (SGLT-2 Is), approved across the seven major markets (7MM), the USA, 5EU (France, Italy, Germany, Spain, UK),...
22 February 2018
CAR-Ts have been hailed as game-changers for patients with relapsed/refractory blood cancers that are resistant to standard treatments.
19 February 2018
During 2017, two new programmed death-ligand 1 inhibitors, Pfizer and Merck’s Bavencio and AstraZeneca’s Imfinzi, were added to the growing list of marketed checkpoint inhibitors.
2 February 2018
Over the past few years, biosimilars have been a hot topic in autoimmunity, and development has recently gained significant momentum in the oncology sector. With the first biosimilar approvals in...
26 January 2018
Yervoy is the first and only immuno-oncology agent to receive approval in the EU in this patient population.
12 January 2018
On January 8, the European Medicine Agency (EMA) accepted Amgen and UCB’s submission for review for use of Evenity (romosozumab), a novel anabolic agent for the treatment of postmenopausal women...